Effects of Antioxidants on Human Macular Pigments
Palabras clave
Abstracto
fechas
| Verificado por última vez: | 01/31/2009 |
| Primero enviado: | 07/16/2008 |
| Inscripción estimada enviada: | 07/16/2008 |
| Publicado por primera vez: | 07/20/2008 |
| Última actualización enviada: | 02/26/2009 |
| Última actualización publicada: | 03/02/2009 |
| Fecha de inicio real del estudio: | 08/31/2004 |
| Fecha estimada de finalización primaria: | 11/30/2007 |
| Fecha estimada de finalización del estudio: | 11/30/2007 |
Condición o enfermedad
Intervención / tratamiento
Dietary Supplement: 1
Dietary Supplement: 2
Fase
Grupos de brazos
| Brazo | Intervención / tratamiento |
|---|---|
| Experimental: 1 lutein | Dietary Supplement: 1 Lutein (12 mg/d) |
| Experimental: 2 Lutein plus green tea extract | Dietary Supplement: 2 lutein (12 mg/d) plus green tea extract (200 mg/d) |
Criterio de elegibilidad
| Edades elegibles para estudiar | 50 Years A 50 Years |
| Sexos elegibles para estudiar | All |
| Acepta voluntarios saludables | si |
| Criterios | Inclusion Criteria: - Normal hematologic parameters, normal serum albumin, normal liver function, normal kidney function, absence of fat malabsorption and no drug intake which would interfere with fat absorption, metabolism or blood clotting - non-smokers Exclusion Criteria: - A history of kidney stones, active small bowel disease or resection, atrophic gastritis, hyperlipidemia, insulin-requiring diabetes, alcoholism, pancreatic disease, or bleeding disorders - Exogenous hormone users - weighing greater than 20% above or below the NHANES median standard - subjects with serum lutein/zeaxanthin concentrations that are more than 150 % of median of normal population (as previously reported in NHANES III at same age group) - early age related macular degeneration, cataract, or glaucoma except for those with age appropriate progression of the eye status. |
Salir
Medidas de resultado primarias
1. macular pigments, Plasma lutein concentrations [Every month - baseline, 1, 2, 3, & 4 months]
